{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:32Z","timestamp":1794047492837,"version":"4.8.0"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective analysis included patients with newly diagnosed MDS (&gt;5% blasts) and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. We factored patient age, TP53 aberration burden, therapy intensity and use of venetoclax in the AML subgroup, and allogeneic hematopoietic stem cell transplantation (HSCT) to interrogate outcomes. TP53 was annotated as high-risk (TP53HR) if &gt;1 mutation, one mutation plus allelic deletion or a single mutation with variant allele frequency (VAF) \u226540%; TP53 low-risk (TP53LR) included a single TP53 mutation VAF &lt;40%. Four-hundred and thirteen patients (291 AML, 122 MDS) at a median age of 69.4 years were included, 350 (85%) with TP53HR (253 AML [87%], 97 [79%] MDS). Overall response (OR) rate was 53% in AML and 62% in MDS. OR and composite complete response (CRc) rates was similar in patients with AML irrespective of treatment intensity, but higher when treated with venetoclax. At a median follow-up of 77 months, median OS was superior in patients with MDS than AML (10.8 vs. 5.9 months). On multivariate analysis (MVA) MDS had lower hazards of death compared to AML, as was TP53LR and HSCT. In the AML cohort, TP53LR and HSCT were favorable on MVA, though venetoclax did not improve survival. Both the diagnosis of MDS or AML and burden of TP53 aberrations dictated outcomes in our analysis and HSCT consistently led to improved survival outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2024.286465","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T03:41:02Z","timestamp":1733974862000},"page":"1304-1315","source":"Crossref","is-referenced-by-count":17,"title":["Clinical interrogation of &lt;i&gt;TP53&lt;\/i&gt; aberrations and its impact on survival in patients with myeloid neoplasms"],"prefix":"10.3324","volume":"110","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naszrin","family":"Arani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankalp","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"75557","doi-asserted-by":"crossref","unstructured":"Daver NG, Iqbal S, Huang J. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023; 98(8):1176-1184.","DOI":"10.1002\/ajh.26941"},{"key":"75558","doi-asserted-by":"crossref","unstructured":"Daver NG, Maiti A, Kadia TM. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 2022; 12(11):2516-2529.","DOI":"10.1158\/2159-8290.CD-22-0332"},{"key":"75559","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Kadia T, DiNardo C. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021; 11(2):41.","DOI":"10.1038\/s41408-021-00425-3"},{"key":"75560","doi-asserted-by":"crossref","unstructured":"Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023; 34(2):141-151.","DOI":"10.1016\/j.annonc.2022.11.004"},{"key":"75561","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Long N, Saultz J. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023; 7(9):1899-1909.","DOI":"10.1182\/bloodadvances.2022009010"},{"key":"75562","doi-asserted-by":"crossref","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925.","DOI":"10.1158\/2159-8290.CD-19-0125"},{"key":"75563","doi-asserted-by":"crossref","unstructured":"Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017; 130(6):699-712.","DOI":"10.1182\/blood-2017-02-763086"},{"key":"75564","doi-asserted-by":"crossref","unstructured":"Desai PN, Wang B, Reville PK. Single-cell characterization of TP53-mutated AML patients treated with frontline azacitidine, venetoclax, and magrolimab reveals mechanisms of response and resistance. Blood. 2023; 142(Suppl 1):64.","DOI":"10.1182\/blood-2023-187307"},{"key":"75565","doi-asserted-by":"crossref","unstructured":"Daver N, Senapati J, Maiti A. Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML. Blood. 2022; 140(Suppl 1):141-144.","DOI":"10.1182\/blood-2022-170188"},{"key":"75566","doi-asserted-by":"crossref","unstructured":"Senapati J, Loghavi S, Reville PK. Outcomes of patients (pts) with newly diagnosed acute myeloid leukemia (AML) and TP53 mutation\/loss treated on the phase 2 study of venetoclax (Ven) added to alternating cladribine (Clad) plus low-dose cytarabine (LDAC) and azacitidine (Aza): a subgroup analysis. Blood. 2023; 142(Suppl 1):4282.","DOI":"10.1182\/blood-2023-179380"},{"key":"75567","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Goldberg AD, Winer ES. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023; 10(4):e272-e283.","DOI":"10.1016\/S2352-3026(22)00403-3"},{"key":"75568","doi-asserted-by":"crossref","unstructured":"Daver NG, Iqbal S, Renard C. Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol. 2023; 16(1):19.","DOI":"10.1186\/s13045-023-01417-5"},{"key":"75569","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz KW, Wei AH. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022; 28(24):5272-5279.","DOI":"10.1158\/1078-0432.CCR-22-1183"},{"key":"75570","doi-asserted-by":"crossref","unstructured":"Wei AH, Panayiotidis P, Montesinos P. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022; 140(25):2754-2756.","DOI":"10.1182\/blood.2022016963"},{"key":"75571","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD. ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022; 140(Suppl 1):1441-1444.","DOI":"10.1182\/blood-2022-169509"},{"key":"75572","doi-asserted-by":"crossref","unstructured":"Bataller A, Bazinet A, DiNardo CD. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024; 8(4):927-935.","DOI":"10.1182\/bloodadvances.2023011757"},{"key":"75573","doi-asserted-by":"crossref","unstructured":"Grob T, Al Hinai ASA, Sanders MA. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354.","DOI":"10.1182\/blood.2021014472"},{"key":"75574","doi-asserted-by":"crossref","unstructured":"Bahaj W, Kewan T, Gurnari C. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023; 16(1):91.","DOI":"10.1186\/s13045-023-01480-y"},{"key":"75575","doi-asserted-by":"crossref","unstructured":"Short NJ, Montalban-Bravo G, Hwang H. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020; 4(22):5681-5689.","DOI":"10.1182\/bloodadvances.2020003120"},{"key":"75576","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. Cancer. 2022; 128(8):1568-1570.","DOI":"10.1002\/cncr.34119"},{"key":"75577","doi-asserted-by":"crossref","unstructured":"Estey E, Hasserjian RP, D\u00f6hner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022; 139(3):323-332.","DOI":"10.1182\/blood.2021011304"},{"key":"75578","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Garcia-Manero G, Pierce S. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016; 91(2):227-232.","DOI":"10.1002\/ajh.24252"},{"key":"75579","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"75580","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"75581","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"75582","unstructured":"ISCN 2016: an International System for Human Cytogenomic Nomenclature. S.Karger AG. 2016."},{"key":"75583","doi-asserted-by":"crossref","unstructured":"Ok CY, Loghavi S, Sui D. Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019; 104(2):305-311.","DOI":"10.3324\/haematol.2018.191148"},{"key":"75584","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020; 4(3):482-495.","DOI":"10.1182\/bloodadvances.2019001101"},{"key":"75585","doi-asserted-by":"crossref","unstructured":"Short NJ, Montalban-Bravo G, Hwang H. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020; 4(22):5681-5689.","DOI":"10.1182\/bloodadvances.2020003120"},{"key":"75586","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"75587","doi-asserted-by":"crossref","unstructured":"Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425.","DOI":"10.1182\/blood-2005-10-4149"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11870\/77884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11870\/78413","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11870\/77884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:51Z","timestamp":1794046071000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286465","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}